NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its loss also narrowed sharply to $18 million from $199 million. Most of its revenue came from sales of Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy to treat cancer.
“Momentum for Carvykti is growing,” said Legend CEO Huang Ying, commenting on the drug that has become Legend’s primary revenue source since its approval by the FDA in the U.S. in 2022. “We look forward to starting commercial production at our Obelisc facility in Belgium later this year in order to meet the growing demand, and we remain laser-focused on increasing our manufacturing capacity.”
Related Articles
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
BRIEF: Fosun Pharma raises stake in Henlius
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
-
Yalla revenue growth returns to double-digits ahead of new gaming push
YALA.US
